A new day is dawning for neuroscience, at least according to some big biotechs, who are investing aggressively in the challenging therapeutic area despite investor reservations. Biogen Inc. took on neuroscience as a core research area several years ago, and it appears the company is as committed to the space as ever under Exec VP-R&D Michael Ehlers, an experienced neuroscientist who took over the role in April. Now Celgene Corp. also has its eye on building a new neuroinflammation franchise.
Neuroscience Reaches A New Inflection Point, Big Biotechs Say
Celgene and Biogen are investing in the challenging therapeutic area, fueled by advances in science, growing understanding of the role inflammation may play in neurodegenerative diseases and improved tools for measuring efficacy.
